echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves Zemdri (plazomicin) for treatment of complex urinary tract infections

    FDA approves Zemdri (plazomicin) for treatment of complex urinary tract infections

    • Last Update: 2020-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, Achaogen(announcing that the U.SFDA(approved for its Zemdri (plazomicin) for patients with complex urinary tract infections (cUTI) caused by certain Ecoli infections, including those with pynoreneutic nephritisabout Zemdri
    Zemdri is an intravenousdrug(administered once a day)It is worth mentioning that this approval makes Zemdri the only daily treatment for cUTIZemdri is designed to be an antibiotic that can be used against aminoglycoside modifiers, the most common aminoglycoside resistance mechanism in the EcoliZemdri is a new generation of aminoglycoside antibiotics with anti-specific Ecoli activity, including CRE (carbon ilostenin antibiotic resistance) and Ecoli (ultra-broad spectrum beta-lactamase) producedFDA approval is based on Zemdri's EPIC ClinicalTrial ( The experimental results showthat that Zemdri successfully achieved the main therapeutic end of non-performance compared with meropenem Compared to Meropinan, patients treated with Zemdri had a significant overall cure rate (81.7% VS 70.1%) and the elimination of the proportion of infected microorganisms The FDA-approved antibiotic folds at 2 mcg / mL, i.e greater than 99% e coli, C.B.A And Gyeloba are sensitive to Zemdri at the data point in addition , Zemdri has shown good tolerance and safety
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.